1-(3-吡咯烷基)吡唑二盐酸盐 | 1242339-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(3-吡咯烷基)吡唑二盐酸盐
• 英文名称: 1H-Pyrazole, 1-(3-pyrrolidinyl)-, hydrochloride (1:2)
• 英文别名: 1-pyrrolidin-3-ylpyrazole;hydrochloride
• CAS: 1242339-08-7
• 化学式: C7H12ClN3
• 分子量: 173.64
• InChiKey: NTSWFLOEQVDSJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.84
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] AZA-CYANOQUINOLINONE PDE9 INHIBITORS<br/>[FR] AZA-CYANOQUINOLINONE UTILES EN TANT QU'INHIBITEURS DE PDE9
  申请人：MERCK SHARP & DOHME

  公开号：WO2017019723A1

  公开（公告）日：2017-02-02

  The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及可能用作治疗与磷酸二酯酶9（PDE9）相关的中枢神经系统疾病的治疗剂的氮杂喹啉酮化合物。本发明还涉及利用这些化合物治疗神经学和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• PDE9 INHIBITOR AND USE THEREOF
  申请人：Nanjing Transthera Biosciences Co. Ltd.

  公开号：EP3689876A1

  公开（公告）日：2020-08-05

  The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.

  本发明属于医药技术领域，尤其涉及式（I）所示的PDE9抑制剂化合物或其药学上可接受的盐或立体异构体，还涉及该化合物的药物制剂和药物组合物及其用途。X1、X2、X3、X4、R1、R2、环 A、L 和 m 如描述中所定义。这些化合物可用于制备治疗或预防由 PDE9 介导的相关疾病的药物。
• Substituted quinolinones as PDE9 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10376504B2

  公开（公告）日：2019-08-13

  The present invention is directed to azacyanoquinolinone compounds of the general structural formula: (wherein R5 and R6 are defined herein) which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及结构通式为氮杂氰基喹啉酮的化合物： (其中R5和R6在此定义）的氮杂氰基喹啉酮化合物，其可用作治疗与磷酸二酯酶9（PDE9）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病或亨廷顿氏病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• PDE9 inhibitor and use thereof
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US10889591B2

  公开（公告）日：2021-01-12

  The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.

  本发明属于医药技术领域，尤其涉及式（I）所示的PDE9抑制剂化合物或其药学上可接受的盐或立体异构体，还涉及该化合物的药物制剂和药物组合物及其用途。X1、X2、X3、X4、R1、R2、环 A、L 和 m 如描述中所定义。这些化合物可用于制备治疗或预防由 PDE9 介导的相关疾病的药物。
• AZA-CYANOQUINOLINONE PDE9 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180214439A1

  公开（公告）日：2018-08-02

  The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.